FRTX vs. PRPH, CING, NERV, SPRB, NRSN, HCWB, FLGC, SNSE, IMNN, and BGXX
Should you be buying Fresh Tracks Therapeutics stock or one of its competitors? The main competitors of Fresh Tracks Therapeutics include ProPhase Labs (PRPH), Cingulate (CING), Minerva Neurosciences (NERV), Spruce Biosciences (SPRB), NeuroSense Therapeutics (NRSN), HCW Biologics (HCWB), Flora Growth (FLGC), Sensei Biotherapeutics (SNSE), Imunon (IMNN), and Bright Green (BGXX). These companies are all part of the "pharmaceutical products" industry.
Fresh Tracks Therapeutics vs.
Fresh Tracks Therapeutics (NASDAQ:FRTX) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.
25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by insiders. Comparatively, 20.7% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Fresh Tracks Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500.
ProPhase Labs has a consensus target price of $11.00, suggesting a potential upside of 1,706.24%. Given ProPhase Labs' stronger consensus rating and higher probable upside, analysts plainly believe ProPhase Labs is more favorable than Fresh Tracks Therapeutics.
ProPhase Labs received 114 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 50.00% of users gave ProPhase Labs an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote.
In the previous week, Fresh Tracks Therapeutics' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.
Fresh Tracks Therapeutics has higher earnings, but lower revenue than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fresh Tracks Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. Fresh Tracks Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.
Summary
Fresh Tracks Therapeutics and ProPhase Labs tied by winning 8 of the 16 factors compared between the two stocks.
Get Fresh Tracks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresh Tracks Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FRTX) was last updated on 1/21/2025 by MarketBeat.com Staff
